We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+237.58%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$4.59B
AUM Growth
+$706M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
44
New
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
+$53.1M
2
+$41M
3
+$37.7M
4
ACHV icon
Achieve Life Sciences
ACHV
+$36.3M
5
KLRA
Kailera Therapeutics
KLRA
+$24.2M

Top Sells

Rank Stock Value
1
+$133M
2
+$99.9M
3
+$65.7M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$42.5M
5
TRVI icon
Trevi Therapeutics
TRVI
+$1.45K

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$6.15B
$899M 19.58%
7,679,684
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.26B
$613M 13.35%
18,088,902
+1,145,128
ERAS icon
3
Erasca
ERAS
$6.33B
$458M 9.96%
24,975,188
+300,000
MBX
4
MBX Biosciences
MBX
$3.2B
$367M 8%
6,652,013
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.34B
$259M 5.64%
9,874,511
TRVI icon
6
Trevi Therapeutics
TRVI
$2.68B
$185M 4.04%
9,939,447
-100
KRYS icon
7
Krystal Biotech
KRYS
$9.85B
$179M 3.9%
481,307
MAZE
8
Maze Therapeutics
MAZE
$1.62B
$150M 3.27%
5,032,915
+465,641
PHAT icon
9
Phathom Pharmaceuticals
PHAT
$748M
$135M 2.95%
12,466,489
PVLA
10
Palvella Therapeutics
PVLA
$2.17B
$135M 2.94%
882,400
BBIO icon
11
BridgeBio Pharma
BBIO
$16.2B
$115M 2.51%
1,548,139
-1,900,000
IRON icon
12
Disc Medicine
IRON
$3.08B
$99.1M 2.16%
1,354,852
CYTK icon
13
Cytokinetics
CYTK
$10.6B
$98.8M 2.15%
1,159,879
DYN icon
14
Dyne Therapeutics
DYN
$4.86B
$70M 1.53%
3,153,082
ASND icon
15
Ascendis Pharma A/S
ASND
$16.3B
$60.1M 1.31%
225,155
+91,822
SVRA icon
16
Savara
SVRA
$1.1B
$59.9M 1.3%
9,720,852
PBLS
17
Parabilis Medicines Inc
PBLS
$4.81B
$52.6M 1.14%
+1,920,805
AURA icon
18
Aura Biosciences
AURA
$846M
$50.4M 1.1%
7,100,000
+2,000,000
ACHV icon
19
Achieve Life Sciences
ACHV
$772M
$49.7M 1.08%
+7,614,836
VOR icon
20
Vor Biopharma
VOR
$1.38B
$46.8M 1.02%
2,543,939
ALLO icon
21
Allogene Therapeutics
ALLO
$701M
$46.7M 1.02%
22,446,668
+18,650,000
TARS icon
22
Tarsus Pharmaceuticals
TARS
$3.12B
$45.9M 1%
728,644
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.48B
$40.1M 0.87%
4,009,240
ALKS icon
24
Alkermes
ALKS
$8.3B
$36.7M 0.8%
700,647
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$5.2B
$36.4M 0.79%
1,438,198
1
2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2026 Portfolio in Review

As of Q2 2026, Frazier Life Sciences Management held 44 positions worth $4.59B, up 18% from $3.89B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Frazier Life Sciences Management's Q2 2026 filing shows 6 new, 8 increased, 2 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M. The largest sale was BridgeBio Pharma, an estimated $133M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Frazier Life Sciences Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,920,805 shares worth $52.6M.
  • Frazier Life Sciences Management added most to Allogene Therapeutics in Q2 2026, an estimated $41M increase.
  • Frazier Life Sciences Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $133M.
  • Frazier Life Sciences Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $99.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 74% of its $4.59B portfolio in Q2 2026.
  • Frazier Life Sciences Management opened 6 new positions and closed 3 in Q2 2026.
  • Frazier Life Sciences Management's portfolio value rose 18% quarter-over-quarter to $4.59B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.